CYP21A2 and congenital adrenal hyperplasia: Using the Minnesota family samples with 2 or more pathogenic CYP21A2 variants and known phasing, Greene et al (31) showed that manual determination of phasing by using an allele-specific PCR and a total of 5 variant sites can improve assessment of CAH disease risk in a newborn without the requirement of family studies for genetic phasing.